Today, we shared some big news! Medtronic announced its intent to separate our Diabetes business into a standalone, public company. This next chapter enables us to relentlessly focus and accelerate strategic investments in areas that will most benefit you — from breakthrough innovations, five-star customer experience to scaling automated manufacturing to meet growing demand for our technologies. We’re unique in Medtronic as a direct-to-consumer business so this is a win-win as it allows both companies to strategically focus on our core strengths.

I wanted to personally reach out regarding the recent approval of our Simplera Sync™ sensor. While this should have been a moment of celebration, I understand many of you were disappointed by our communication. Over the past few days, I’ve had the privilege of speaking with many of you and listening to your concerns.

Read Que Dallara's reflections on highlights from 2023.

Read stories about our Medtronic Champions who are getting things back with the help of the MiniMed 780G system. Que wants to know: what did you "get back"?

Join the others globally benefiting from the MiniMed™ 780G system! Now approved in the U.S.

Discover the vibrant #MedtronicChampion community. Hear inspiring stories of individuals living with diabetes.

Reflection on significant moments and insights in diabetes from 2022. Explore advancements, trends and experiences.

Join Que in celebrating the vibrant diabetes community. Explore stories, insights, and experiences that unite us all.

Que introduces My Insights, an empowering platform sharing personal stories and invaluable insights on diabetes management.